JP2012527486A5 - - Google Patents

Download PDF

Info

Publication number
JP2012527486A5
JP2012527486A5 JP2012512087A JP2012512087A JP2012527486A5 JP 2012527486 A5 JP2012527486 A5 JP 2012527486A5 JP 2012512087 A JP2012512087 A JP 2012512087A JP 2012512087 A JP2012512087 A JP 2012512087A JP 2012527486 A5 JP2012527486 A5 JP 2012527486A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
hsv
polypeptide
vaccine formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012512087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012527486A (ja
JP5771605B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/035998 external-priority patent/WO2010135747A1/en
Publication of JP2012527486A publication Critical patent/JP2012527486A/ja
Publication of JP2012527486A5 publication Critical patent/JP2012527486A5/ja
Application granted granted Critical
Publication of JP5771605B2 publication Critical patent/JP5771605B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012512087A 2009-05-22 2010-05-24 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法 Expired - Fee Related JP5771605B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US18078409P 2009-05-22 2009-05-22
US61/180,784 2009-05-22
US23562809P 2009-08-20 2009-08-20
US61/235,628 2009-08-20
US24062609P 2009-09-08 2009-09-08
US24058709P 2009-09-08 2009-09-08
US61/240,587 2009-09-08
US61/240,626 2009-09-08
US30591810P 2010-02-18 2010-02-18
US61/305,918 2010-02-18
PCT/US2010/035998 WO2010135747A1 (en) 2009-05-22 2010-05-24 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015129772A Division JP6096839B2 (ja) 2009-05-22 2015-06-29 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法

Publications (3)

Publication Number Publication Date
JP2012527486A JP2012527486A (ja) 2012-11-08
JP2012527486A5 true JP2012527486A5 (https=) 2013-07-04
JP5771605B2 JP5771605B2 (ja) 2015-09-02

Family

ID=43126545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012512087A Expired - Fee Related JP5771605B2 (ja) 2009-05-22 2010-05-24 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法
JP2015129772A Expired - Fee Related JP6096839B2 (ja) 2009-05-22 2015-06-29 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015129772A Expired - Fee Related JP6096839B2 (ja) 2009-05-22 2015-06-29 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法

Country Status (17)

Country Link
US (3) US8617564B2 (https=)
EP (3) EP3756684A1 (https=)
JP (2) JP5771605B2 (https=)
KR (1) KR101746872B1 (https=)
CN (2) CN106924728B (https=)
AU (1) AU2010249330B2 (https=)
BR (1) BRPI1012811A2 (https=)
CA (1) CA2797937C (https=)
ES (1) ES2732815T3 (https=)
IL (1) IL216508A (https=)
MX (1) MX2011012347A (https=)
MY (1) MY159500A (https=)
NZ (1) NZ597182A (https=)
RU (1) RU2585961C9 (https=)
SG (1) SG176207A1 (https=)
WO (2) WO2010135749A1 (https=)
ZA (1) ZA201109444B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
JP6055776B2 (ja) * 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
WO2012139099A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus vaccine
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
AU2012340712B2 (en) * 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
WO2014052971A1 (en) * 2012-09-30 2014-04-03 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsions
CN103074337B (zh) * 2012-12-04 2014-07-09 昆明寰基生物芯片产业有限公司 一段单纯疱疹病毒dna序列及应用
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
EP3943106A1 (en) 2014-03-03 2022-01-26 Albert Einstein College of Medicine Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
DK3411388T3 (da) 2016-02-01 2021-12-13 Simplexia Ab Trunkeret glycoprotein g af herpes simplex virus 2
RS60410B1 (sr) * 2016-04-08 2020-07-31 Krystal Biotech Inc Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
KR101962683B1 (ko) * 2016-09-28 2019-03-27 주식회사 에스엘백시젠 Hsv-2 감염 예방 및 치료용 dna 백신
WO2018200613A1 (en) * 2017-04-26 2018-11-01 Merck Sharp & Dohme Corp. Hsv antigenic peptides and hsv protein vaccines
AU2018316811B2 (en) * 2017-08-17 2023-07-13 The Trustees Of The University Of Pennsylvania Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
EP3921334A1 (en) 2019-02-08 2021-12-15 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
US20240108747A1 (en) 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
BR112021018694A2 (pt) 2019-03-21 2021-11-30 Codiak Biosciences Inc Vesículas extracelulares para distribuição de vacina
CN109943592B (zh) * 2019-04-29 2020-11-17 华中农业大学 含猪伪狂犬病病毒gD蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用
CN110845583A (zh) * 2019-11-18 2020-02-28 维塔恩(广州)医药有限公司 水痘带状疱疹病毒相关抗原短肽及其应用
CN110724181A (zh) * 2019-11-18 2020-01-24 维塔恩(广州)医药有限公司 单纯疱疹病毒相关抗原短肽及其应用
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) * 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
EP0471778A1 (en) * 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
CA2088600C (en) * 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
DK31991D0 (da) * 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP0708833A1 (en) 1993-06-08 1996-05-01 Abbott Laboratories Herpes simplex virus type-2 protease
EP0714399A4 (en) 1993-08-20 1999-01-27 Smithkline Beecham Corp HSV-2 UL26 GEN, ENVELOPE PROTEINS, IMMUNOASSAYS AND PROTEAS INHIBITORS
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) * 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996032962A1 (en) * 1995-04-21 1996-10-24 The University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
KR100564268B1 (ko) * 1996-10-23 2006-03-27 와이어쓰 백신
CN1324139C (zh) * 1996-10-23 2007-07-04 惠氏 疫苗
CA2270282A1 (en) 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
EP0984790A1 (en) 1997-06-02 2000-03-15 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) * 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
NZ506602A (en) * 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
US6375952B1 (en) * 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
CA2375320C (en) * 1999-06-10 2013-02-19 Merial Dna vaccines for pets or for animals used in sports
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP1222281B1 (en) * 1999-09-30 2006-11-15 University of Washington Immunoligically significant herpes simplex virus antigens
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
ES2258987T3 (es) * 1999-12-17 2006-09-16 Wyeth Holdings Corporation Vacuna para reforzar las respuestas inmunitarias al virus del herpes simple.
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
AU2001273128C1 (en) 2000-06-29 2006-09-21 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US7569218B2 (en) * 2000-07-27 2009-08-04 The Trustees Of The University Of Pennsylvania Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US20040220076A1 (en) * 2000-11-16 2004-11-04 Laure Aurelian Prevention of recurrent viral disease
US6867000B2 (en) * 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
JP2006512401A (ja) 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
ATE488249T1 (de) * 2001-07-31 2010-12-15 Univ Washington Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
WO2003020108A2 (en) 2001-09-04 2003-03-13 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
DK1523582T3 (da) * 2002-07-18 2009-03-02 Univ Washington Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
US7267940B2 (en) * 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
CA2538794C (en) * 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20120027841A1 (en) 2004-01-07 2012-02-02 Biomedical Research Models, Inc. Novel mucosal vaccination approach for herpes simplex virus type-2
AU2006338570B2 (en) * 2005-11-18 2013-07-11 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
CA2645507A1 (en) 2006-03-10 2007-09-20 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
CA2658484A1 (en) * 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
WO2008030560A2 (en) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Hsv-1 and hsv-2 vaccines and methods of use thereof
US9297803B2 (en) 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US9284355B2 (en) * 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2009006618A2 (en) 2007-07-05 2009-01-08 University Of Kansas Herpes simplex virus mutant icp0 protein
US20130273088A1 (en) 2007-07-06 2013-10-17 Anthony Lawrence Cunningham Epitopes of herpes simplex virus
EP2293814A4 (en) * 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
AU2009266924B2 (en) 2008-07-01 2015-12-10 Genocea Biosciences, Inc. Antigen screening system
JP2012512257A (ja) 2008-12-17 2012-05-31 ジェノセア バイオサイエンシーズ， インコーポレイテッド クラミジア抗原およびその使用
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
CA2754592A1 (en) 2009-03-09 2010-09-16 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2011106607A2 (en) 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
WO2012054755A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes

Similar Documents

Publication Publication Date Title
JP2012527486A5 (https=)
RU2011147153A (ru) Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
JP7792339B2 (ja) コロナウイルスワクチン製剤
CN112220920B (zh) 一种重组新型冠状病毒疫苗组合物
JP2015178529A5 (https=)
JP2023162283A5 (https=)
JP3901731B2 (ja) サポニンおよびステロールを含有するワクチン
White Varicella-zoster virus vaccine
Dupont et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine
US20230084300A1 (en) Prevention and treatment of infections including those caused by coronavirus
JPH08510749A (ja) 呼吸器シンシチウムウイルスに対するワクチンのためのアジュバント
JP2014506562A5 (ja) 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用
JP2024511412A (ja) コロナウイルスワクチン製剤
JP2018500322A (ja) ワクチン接種
EP3125930B1 (en) Novel methods for inducing an immune response
CN110621339A (zh) 疫苗接种
US20250339511A1 (en) Nucleic acid vaccine against monkeypox virus and use thereof
Pan et al. A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh (αK): A phase I study
JP2013545761A5 (https=)
Misra et al. Current updates on COVID-19 vaccines
US20030219448A1 (en) Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
WO2024041612A1 (zh) 一种正痘病毒属mRNA疫苗及其制备方法和用途
JP2014534262A5 (https=)
Kim et al. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
GB2607262A (en) Prevention and treatment of infections including those caused by coronavirus